- May 30, 2019SAN DIEGO, May 30, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of…
- May 9, 2019SAN DIEGO, May 9, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment…
- April 29, 2019SAN DIEGO, April 29, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of…
- April 12, 2019– Developing Oral Therapies with Best-in-Class Potential – – Lead Program, IMU-838, Already Advanced into Phase 2 Studies in Ulcerative…
- April 2, 2019Planegg-Martinsried, Germany, April 2, 2019 –Immunic AG, a privately held clinical-stage biotechnology company, today announced that Daniel Vitt, Ph.D., Chief Executive…
- February 28, 2019Planegg-Martinsried, Germany, February 28, 2019 – Immunic AG (Immunic), a privately held clinical-stage biotechnology company, today announced that management will participate in…
- February 26, 2019Planegg-Martinsried, Germany, February 26, 2019 – Immunic AG (Immunic), a privately held clinical-stage biotechnology company, today announced enrollment of the first patient…
- February 6, 2019Planegg-Martinsried, Germany, February 6, 2019 – Immunic AG (Immunic), a privately-held clinical-stage biotechnology company, today announced that Daniel Vitt, Ph.D., Chief Executive Officer…
- January 7, 2019San Diego, CA, USA and Planegg-Martinsried, Germany, January 7, 2019 – Vital Therapies, Inc. (Nasdaq: VTL), and Immunic AG (Immunic), a private clinical-stage biotechnology…
